Revenue and Profit Forecast - The total revenue for 2024 is expected to be ¥885,628.21, a decrease of 50.24% compared to the previous year[5] - The net profit attributable to shareholders is projected to be -¥351,717,025.37, reflecting a year-on-year decline of 16.88%[5] - The basic earnings per share is estimated at -¥1.26, down 14.55% from the previous year[5] Assets and Equity - Total assets at the end of the reporting period are expected to be ¥1,544,584,166.38, an increase of 6.21% from the beginning of the period[6] - Shareholders' equity attributable to the company is projected to be ¥557,564,127.86, a decrease of 38.52% compared to the beginning of the period[6] - The net asset per share attributable to shareholders is expected to be ¥1.98, down 38.56% from the beginning of the period[6] Factors Affecting Financial Performance - The decline in revenue is primarily due to a lack of commercialization and a significant reduction in sales of research testing reagents[8] - Increased R&D expenses and personnel costs contributed to the net profit decline, alongside higher depreciation and interest expenses[8] - The company remains in a pre-profit state with no products launched for sale, impacting overall financial performance[9] Caution for Investors - Investors are advised to note that the financial data presented is preliminary and unaudited, emphasizing the need for caution[10]
康乐卫士(833575) - 2024 Q4 - 年度业绩